Replimune (REPL) Shares Plunge 19% as FDA Issues Second Rejection for Melanoma Treatment

Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial design and controls.

The post Replimune (REPL) Shares Plunge 19% as FDA Issues Second Rejection for Melanoma Treatment appeared first on Blockonomi.